AptarGroup, Inc. (ATR) Balance Sheet

The balance sheet has expanded steadily, with total assets increasing by approximately 16% since 2024Q1, driven by both organic growth and acquisitions, as evidenced by rising goodwill from $953M to $1.1B. However, total debt has also climbed from $1.1B to $1.4B, lifting the debt-to-equity ratio from 0.49 to 0.53, suggesting that growth is increasingly funded by borrowings. This trend appears manageable given the company's strong cash generation, but investors should monitor whether leverage continues to rise without commensurate profitability gains.

Despite the recent increase, ATR's leverage remains conservative, with a debt-to-equity ratio of 0.53 and debt-to-assets of approximately 27%, compared to industry peers that often exceed 1.0. The debt increase appears tied to acquisition activity, as goodwill rose by $150M over the period, suggesting strategic use of debt rather than operational necessity. Given the company's stable cash flows and low leverage, refinancing risk appears minimal, but the rising trend warrants monitoring to ensure it does not erode financial flexibility.

The asset base is increasingly weighted toward intangible assets, with goodwill climbing from $936M to $1.1B, likely reflecting acquisitions in the Pharma segment. This suggests a strategic pivot toward higher-value drug delivery systems, which may justify the premium valuation relative to packaging peers. However, the growing goodwill balance raises impairment risk if Pharma growth disappoints, and investors should monitor the carrying value relative to segment performance.

The equity base has strengthened primarily through retained earnings, which grew by $500M over ten quarters, reflecting solid net income generation. Despite aggressive share repurchases, which totaled $50M in 2026Q2, equity still increased, indicating that earnings retention is outpacing capital returns. This suggests a healthy balance between rewarding shareholders and reinvesting in the business, though the rising SBC (averaging $10.6M per quarter) may dilute existing shareholders over time.

While the current ratio has improved, indicating better short-term solvency, the absolute cash position has declined from $223.8M in 2024Q4 to $190.4M in 2026Q2, partly due to debt repayments and capital expenditures. The company maintains a comfortable liquidity buffer relative to its operating costs, but the declining cash trend, combined with rising debt, suggests that liquidity is being deployed for growth rather than retained. Investors should monitor whether cash generation remains sufficient to cover debt service and dividends without straining the balance sheet.